Clinical Trials
Sep 19, 2026 · 1 min read · 45,899 views
Alzheon outlines plans for major fundraising round despite Phase 3 miss for Alzheimer's drug
S
Sophia Reyes
Editorial · Sep 19, 2026
Alzheon, a biotech that has been attempting to treat Alzheimer's with a checkered drug candidate for more than a decade, is plotting an up to $500 million equity sale
← Previous
Lei Lei Wu - Page 53 - Endpoints News
Next →
Roche says Carmot-acquired shot delivers Phase 2 win in overweight patients with diabetes
